EsoBiotec

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions #Oncology

AstraZeneca buys in vivo cell therapy specialists EsoBiotec

AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific… Read More

#Business & Investment #News

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions

AstraZeneca acquires in vivo cell therapy developer

EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.  AstraZeneca will make an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones.  The EsoBiotec Engineered NanoBody… Read More

#Business & Investment #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Phase I trial

First in vivo BCMA CAR-T candidate reaches the clinic

A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.  The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More

#Editor's Choice #News